Date: 2017-11-13
Type of information: Collaboration agreement
Compound: Cas9 mRNA constructs
Company: Crispr Therapeutics (Switzerland - UK) Casebia Therapeutics (UK) Curevac (Germany)
Therapeutic area: Hepatic diseases - Liver diseases
Type agreement: collaboration
Action mechanism:
Disease: liver diseases
Details:
- • On November 13, 2017, CRISPR Therapeutics, Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer for developing CRISPR-based therapeutics in select disease areas, and CureVac, a biopharmaceutical company pioneering mRNA-based drugs, announced they have signed a collaboration agreement. Under the terms of the agreement, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity. CRISPR Therapeutics and Casebia have obtained an exclusive license to the improved constructs for use in three of their in vivo gene-editing programs in liver diseases. CureVac will also provide mRNA manufacturing through clinical development and commercialization of the three programs.
Financial terms:
- CureVac will receive an upfront payment and research funding, and will be eligible to receive development and commercial milestones and royalties on commercialized products arising from the collaboration.
Latest news:
Is general: Yes
